We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 12, 2022

PD-L1 Expression and TIL Status Predict Longer PFS With Chemoradiation Followed by Durvalumab

European Journal of Cancer


Additional Info

European Journal of Cancer
Baseline PD-L1 Expression and Tumour-Infiltrated Lymphocyte Status Predict the Efficacy of Durvalumab Consolidation Therapy After Chemoradiotherapy in Unresectable Locally Advanced Patients With Non-Small-Cell Lung Cancer
Eur. J. Cancer 2022 Feb 01;162(xx)1-10, M Shirasawa, T Yoshida, T Imabayashi, K Okuma, Y Matsumoto, K Masuda, Y Shinno, Y Okuma, Y Goto, H Horinouchi, T Tsuchida, N Yamamoto, Y Nakayama, SI Watanabe, N Motoi, Y Ohe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading